Kriya
Kriya Therapeutics is a biopharmaceutical company developing gene therapies for chronic diseases, including its lead product KRIYA-825 for Geographic Atrophy.
Secondary Market Price
Secondary Market Price
How Kriya Measures Up
To help you manage your Kriya equity, Prospect has run the company through our machine learning model.
Prospect Rating
Exit Risk
Funding Stage
Series D
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Kriya's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Kriya Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Kriya's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Kriya Therapeutics is a biopharmaceutical company founded in 2019 that develops gene therapies for chronic diseases, with a focus on ophthalmology, metabolic disease, and neurology. The company’s pipeline includes AAV-based gene therapies for conditions such as type 1 and type 2 diabetes and severe obesity. Its lead project, KRIYA-825, is a one-time, injectable gene therapy for Geographic Atrophy. Since its founding by Shankar Ramaswamy, Roger Jeffs, and Fraser Wright, Kriya has raised over $900 million in funding and operates out of facilities in Research Triangle Park, North Carolina, and Palo Alto, California.
The company is focused on advancing its pipeline of gene therapies through clinical development, supported by investments in its technology and manufacturing capabilities. Recent developments indicate a period of expansion, including the closing of a $320 million Series D financing round and the appointment of a new Chief Medical Officer with experience in gene therapy development. Kriya also recently highlighted progress across its pipeline by presenting thirteen abstracts at the American Society of Gene & Cell Therapy’s 28th Annual Meeting.
- Patient Square Capital
- Premji Invest
- Peter Thiel
- Narya Capital
- The T1D Fund
- QVT
- Dexcel Pharma
- Foresite Capital
- Bluebird Ventures
- Transhuman Capital
- Amplo
- Paul Manning
- Asia Alpha
- Woodline Partners LP
- CAM Capital
- Hongkou
- Alumni Ventures
- Lightswitch Capital
- Co-Founder, Chief Executive Officer Shankar Ramaswamy
- Co-Founder, Board Member Roger Jeffs
- Co-Founder, Chief Technology Officer J. Fraser Wright
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Kriya worth joining?
Deciding whether to join a startup like Kriya depends on your personal career goals and risk appetite, as it involves evaluating the company's potential and culture. Tools like Prospect can help you analyze the equity portion of your compensation package to make a more informed decision.
What should I do with my Kriya stock?
Managing private stock involves complex decisions about when to exercise options, sell shares, and how to minimize taxes. Platforms like Prospect provide personalized strategies and tools to help you optimize the value of your equity based on your financial situation.
Can you sell Kriya stock?
Since Kriya is a private company, its stock isn't traded on public exchanges, but you may be able to sell shares during tender offers or on secondary markets. Services like Prospect can help you navigate these opportunities and determine tax-optimal selling strategies.
How can I find the value of my Kriya stock?
The value of private stock is often based on the company's latest 409A valuation or recent funding rounds, but this can be difficult to track. You can use platforms like Prospect, which employ predictive models to help you forecast the potential future value of your equity.
What is Kriya's equity worth?
A private company's total valuation is determined by investors during funding rounds and is not always public. To understand what your personal stake in Kriya could be worth, you can use platforms like Prospect to model your equity's potential value under various scenarios.
What is Kriya's stock ticker symbol?
Kriya does not have a stock ticker symbol because it is a private company and its shares are not available on public stock exchanges. Ticker symbols are only assigned to companies after they go public through an IPO.
Can I buy or sell Kriya stock?
As a private company, Kriya stock is not available for purchase on public markets, and buying opportunities are generally limited to accredited investors in private funding rounds. Selling shares may be possible during specific liquidity events, and tools like Prospect can help existing shareholders navigate these sales.
What is the criteria to buy or invest in Kriya stock?
Investing in private companies is usually restricted to accredited investors who meet certain financial thresholds set by regulators, or to employees who receive equity as compensation. These opportunities are not generally open to the public.
